AbbVie Goodwill and Intangible Assets 2010-2024 | ABBV

AbbVie goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
  • AbbVie goodwill and intangible assets for the quarter ending September 30, 2024 were $101.941B, a 12.4% increase year-over-year.
  • AbbVie goodwill and intangible assets for 2023 were $87.903B, a 11.74% decline from 2022.
  • AbbVie goodwill and intangible assets for 2022 were $99.595B, a 8.06% decline from 2021.
  • AbbVie goodwill and intangible assets for 2021 were $108.33B, a 6.61% decline from 2020.
AbbVie Annual Goodwill and Intangible Assets
(Millions of US $)
2023 $87,903
2022 $99,595
2021 $108,330
2020 $116,000
2019 $34,253
2018 $36,896
2017 $43,344
2016 $44,313
2015 $32,877
2014 $7,375
2013 $8,167
2012 $8,453
2011 $9,010
2010 $9,888
2009 $0
AbbVie Quarterly Goodwill and Intangible Assets
(Millions of US $)
2024-09-30 $101,941
2024-06-30 $93,629
2024-03-31 $95,651
2023-12-31 $87,903
2023-09-30 $90,694
2023-06-30 $95,086
2023-03-31 $97,068
2022-12-31 $99,595
2022-09-30 $100,451
2022-06-30 $103,851
2022-03-31 $106,284
2021-12-31 $108,330
2021-09-30 $109,752
2021-06-30 $111,738
2021-03-31 $113,642
2020-12-31 $116,000
2020-09-30 $117,444
2020-06-30 $119,132
2020-03-31 $33,764
2019-12-31 $34,253
2019-09-30 $34,573
2019-06-30 $36,101
2019-03-31 $36,452
2018-12-31 $36,896
2018-09-30 $42,343
2018-06-30 $42,595
2018-03-31 $43,110
2017-12-31 $43,344
2017-09-30 $43,915
2017-06-30 $44,018
2017-03-31 $44,119
2016-12-31 $44,313
2016-09-30 $44,770
2016-06-30 $44,957
2016-03-31 $32,786
2015-12-31 $32,877
2015-09-30 $33,065
2015-06-30 $33,146
2015-03-31 $7,012
2014-12-31 $7,375
2014-09-30 $7,542
2014-06-30 $7,939
2014-03-31 $8,073
2013-12-31 $8,167
2013-09-30 $8,192
2013-06-30 $8,221
2013-03-31 $8,213
2012-12-31 $8,453
2012-09-30 $8,523
2012-06-30 $8,514
2012-03-31 $8,909
2011-12-31 $9,010
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $9,888
2009-12-31 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $294.353B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94